Ticker > Company >

Aarey Drugs & Pharma share price

Aarey Drugs & Pharmaceuticals Ltd.

NSE: AAREYDRUGS BSE: 524412 SECTOR: Pharmaceuticals & Drugs  21k   27   6

58.96
0 0
NSE: Today, 10:31 AM

Price Summary

Today's High

₹ 58.96

Today's Low

₹ 58.96

52 Week High

₹ 74.8

52 Week Low

₹ 37.35

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

167.18 Cr.

Enterprise Value

196.93 Cr.

No. of Shares

2.84 Cr.

P/E

24.26

P/B

1.22

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  48.32

CASH

1.59 Cr.

DEBT

31.35 Cr.

Promoter Holding

45.44 %

EPS (TTM)

₹  2.43

Sales Growth

-5.57%

ROE

3.82 %

ROCE

6.09%

Profit Growth

24.2 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-5.57%
3 Year4.33%
5 Year2.21%

Profit Growth

1 Year24.2%
3 Year-10.41%
5 Year-6.46%

ROE%

1 Year3.82%
3 Year4.49%
5 Year5.42%

ROCE %

1 Year6.09%
3 Year7.41%
5 Year8.03%

Debt/Equity

0.2406

Price to Cash Flow

-55.84

Interest Cover Ratio

2.2212

CFO/PAT (5 Yr. Avg.)

0.166857964414687

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 45.44 0.00
Jun 2024 45.28 0.00
Mar 2024 45.28 0.00
Dec 2023 50.04 0.00
Sep 2023 50.04 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 77.3397 days.

 Limitations

  • The company has shown a poor profit growth of -10.4139671812615% for the Past 3 years.
  • The company has shown a poor revenue growth of 4.32592834050387% for the Past 3 years.
  • Company has a poor ROE of 4.48500061801246% over the past 3 years.
  • Company has negative cash flow from operations of -2.9938.
  • Tax rate is low at 12.3379.
  • The company has a low EBITDA margin of 1.53853167098449% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 57.83 76.48 210.35 126.91 105.14
Total Expenditure 55.98 73.77 211.79 125.73 101.42
Operating Profit 1.85 2.7 -1.44 1.18 3.73
Other Income 0.84 0.29 5.14 1.58 0.02
Interest 1.27 1.06 1.16 0.96 1.51
Depreciation 0.41 0.47 0.4 0.47 0.49
Exceptional Items 0 0 0 0 0
Profit Before Tax 1.01 1.46 2.15 1.33 1.75
Tax 0.22 -0.44 -0.01 0.09 0.15
Profit After Tax 0.78 1.91 2.15 1.24 1.6
Adjusted EPS (Rs) 0.31 0.75 0.77 0.44 0.57

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 300.09 348.42 492.76 418.96 395.62
Total Expenditure 296.86 343.77 481.37 411.23 391.17
Operating Profit 3.23 4.65 11.4 7.72 4.45
Other Income 6.69 7.01 2.67 2.73 6.96
Interest 1.79 2.44 2.04 2.87 4.38
Depreciation 0.89 0.92 1.99 1.57 1.7
Exceptional Items 0 0 0 0 0
Profit Before Tax 7.24 8.3 10.04 6.01 5.34
Tax 1.45 1.79 3.48 2.24 0.66
Net Profit 5.79 6.51 6.55 3.77 4.68
Adjusted EPS (Rs.) 2.48 2.79 2.58 1.49 1.67

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 23.38 23.38 25.38 25.38 28.05
Total Reserves 68.96 75.48 88.25 92.02 104.72
Borrowings 0.02 0 3.34 4.36 3.22
Other N/C liabilities 1.44 3.37 1.46 1.42 0.75
Current liabilities 100.28 130.8 126.74 168.14 166.55
Total Liabilities 194.08 233.04 245.17 291.32 303.29
Assets
Net Block 12.3 14.26 14.47 13.94 12.96
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0.44 0.4 0.4 0.4 1.38
Loans & Advances 0 0 9.09 6.37 6.36
Other N/C Assets 0 0 2.4 0.01 0.01
Current Assets 181.34 218.38 218.82 270.61 282.59
Total Assets 194.08 233.04 245.17 291.32 303.29
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 7.24 8.3 10.03 6.01 5.34
Adjustment 2.68 3.35 3.99 4.44 5.41
Changes in Assets & Liabilities -5.56 -4.51 -9.93 -9.45 -12.42
Tax Paid -1.5 -1.66 -3.59 -2.28 -1.33
Operating Cash Flow 2.86 5.48 0.5 -1.28 -2.99
Investing Cash Flow -0.92 -2.88 -3.21 0.44 -1.7
Financing Cash Flow -1.8 -2.45 2.25 1.35 5.58
Net Cash Flow 0.13 0.15 -0.46 0.51 0.89

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 50.04 50.04 45.28 45.28 45.44
bina rajesh ghatalia 15.77 15.77 14.27 14.27 14.32
mihir rajesh ghatalia 11.17 11.17 10.11 10.11 10.14
mira mihir ghatalia 2.72 2.72 2.46 2.46 2.47
nimit impex 7.92 7.92 7.16 7.16 7.19
nimit rajesh ghatalia 4.53 4.53 4.10 4.10 4.11
rajesh pranlal ghatalia 0.01 0.01 0.01 0.01 0.01
suraj tradelinks 7.92 7.92 7.16 7.16 7.19
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 49.96 49.96 54.72 54.72 54.56
c g krishnamurthy 1.93 1.93 1.75 1.75 1.75
chetan kiritbhai mehta 1.18 1.18 1.60 1.60 1.07
india opportunities growt... 3.92 3.83 3.40 3.40 2.67
llp - 0.13 0.16 0.14 0.22
zil penil doshi 1.48 1.48 1.34 1.34 1.34
black hawk properties pvt... - - 1.35 1.35 -
vijaykumar b shah - - 1.07 1.07 -

Ratings & Research Reports

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Aarey Drugs & Pharmaceuticals informs about EGM 7 Dec, 12:43 PM Aarey Drugs & Pharmaceuticals informs about financial results 6 Nov, 3:41 PM Aarey Drugs & Pharmaceuticals informs about press release 19 Aug, 1:34 PM Aarey Drugs & Pharma - Quaterly Results 14 Aug, 5:54 PM Aarey Drugs & Pharmaceuticals informs about certificate 10 Jul, 9:51 AM Aarey Drugs & Pharmaceuticals informs about disclosure 30 Apr, 6:13 PM Aarey Drugs and Pharmaceuticals informs about statement of no deviation and variation 12 Apr, 10:06 AM Aarey Drugs & Pharma - Quaterly Results 14 Feb, 4:26 PM Aarey Drugs & Pharma - Quaterly Results 14 Feb, 4:26 PM Aarey Drugs & Pharmaceuticals informs about certificate 10 Oct, 9:34 AM Aarey Drugs & Pharmaceuticals informs about newspaper advertisement 22 Aug, 10:08 AM Aarey Drugs & Pharma - Quaterly Results 14 Aug, 2:58 PM Aarey Drugs & Pharmaceuticals informs about updates 17 Jun, 1:06 PM Aarey Drugs & Pharmaceuticals informs about disclosure 15 May, 4:18 PM Aarey Drugs & Pharma - Quaterly Results 8 Feb, 4:59 PM Aarey Drugs & Pharma - Quaterly Results 8 Feb, 4:59 PM Aarey Drugs & Pharma - Quaterly Results 8 Feb, 4:59 PM Aarey Drugs & Pharma - Quaterly Results 14 Nov, 5:33 PM Aarey Drugs & Pharma - Quaterly Results 14 Nov, 5:33 PM Aarey Drugs & Pharmaceuticals informs about closure of trading window 27 Sep, 4:42 PM Aarey Drugs & Pharmaceuticals informs about disclosure 23 Jun, 4:44 PM Aarey Drugs & Pharmaceuticals informs about newspaper publication 1 Jun, 4:55 PM Aarey Drugs & Pharma - Quaterly Results 30 May, 6:51 PM Aarey Drugs & Pharmaceuticals informs about compliance certificate 19 Apr, 2:43 PM Aarey Drugs & Pharmaceuticals informs about newspaper advertisement 9 Feb, 4:47 PM Aarey Drugs & Pharmaceuticals informs about outcome of board meeting 8 Feb, 3:58 PM Aarey Drugs & Pharmaceuticals informs about unaudited financial results 8 Feb, 3:50 PM Aarey Drugs & Pharma - Quaterly Results 8 Feb, 2:44 PM Aarey Drugs & Pharma - Quaterly Results 8 Feb, 2:44 PM Aarey Drugs & Pharma - Quaterly Results 8 Feb, 2:44 PM Aarey Drugs & Pharmaceuticals informs about confirmation certificate 6 Jan, 4:35 PM Aarey Drugs & Pharmaceuticals informs about disclosure 19 Nov, 3:22 PM Aarey Drugs & Pharmaceuticals informs about consolidated voting results 13 Sep, 4:51 PM Aarey Drugs & Pharmaceuticals informs about outcome of annual general meeting 11 Sep, 11:33 AM Aarey Drugs & Pharmaceuticals informs about outcome of board meeting 4 Jan, 3:21 PM Aarey Drugs & Pharmaceuticals informs about un-audited financial results 16 Dec, 3:30 PM Aarey Drugs & Pharmaceuticals informs about outcome of board meeting 5 Dec, 1:22 PM Aarey Drugs & Pharmaceuticals informs about disclosure of related party transactions 27 Nov, 3:22 PM

Aarey Drugs & Pharma Stock Price Analysis and Quick Research Report. Is Aarey Drugs & Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Aarey Drugs & Pharma and its performance over the period of time. Aarey Drugs & Pharma stock price today is Rs 58.96.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Aarey Drugs & Pharma cash from the operating activity was Rs -2.9938 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Aarey Drugs & Pharma has a Debt to Equity ratio of 0.2406 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Aarey Drugs & Pharma , the EPS growth was 12.3788 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Aarey Drugs & Pharma has OPM of 1.12515131393195 % which is a bad sign for profitability.
     
  • ROE: Aarey Drugs & Pharma have a poor ROE of 3.8172 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Aarey Drugs & Pharma is Rs 58.96. One can use valuation calculators of ticker to know if Aarey Drugs & Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Aarey Drugs & Pharma
X